BioSpace News Archive

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone in fully enrolling 2,500 oncologists into its Tempus Integrated Molecular Evaluation Trial™ Program that seeks to rapidly match patients largely in the community setting to targeted clinical trials.

Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020, at 4:30 p.m. EDT.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders,

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Eiger is changing its 2020 Annual Meeting of Stockholders

Penumbra, Inc. announced that its management team is scheduled to present at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9, 2020.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced that on May 27, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 500 shares of its common stock to 1 new employee under Xeris’ Inducement Equity Plan.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 16,820 stock options.

AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), with a treatment duration of up to 24 months.2 ORIAHNN is the first FDA-approved non-surgical, oral medica

As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study